To date, Europe is faced with a number of challenges to successfully develop innovative and effective, personalised medicine treatments. EPEMED's objectives are to develop
1. A central point of communication for the different parties involved in progressing personalised medicine 2. Optimal routes to deliver personalised medicine treatments to patients 3. A greater understanding of the clinical development of personalised therapeutics through the creation and application of advanced diagnostic tests
Dr. Bruinvels started her work in personalised medicine more than 10 years ago. She has previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's CEO for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange. Anne Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma. She obtained her PhD (neuroscience) from Utrecht University (the Netherlands) and her MSc (pharmacy) from Groningen University (The Netherlands).
EPEMED is a recently formed, not-for-profit organisation. The association
was founded to address issues in personalised medicine that confront the
industry, regulators, payers & insurers as well as governments. EPEMED aims
to provide a platform for the harmonisation of personalised medicine
development and implementation across Eu
Copyright©2010 PR Newswire.
All rights reserved